glp-1analogs
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| glp-1analogs [2026/02/04 11:35] – [Adverse effects and C/I] gary1 | glp-1analogs [2026/05/19 22:02] (current) – [Actions] wh | ||
|---|---|---|---|
| Line 22: | Line 22: | ||
| * 20% reduction in risk of major adverse cardiovascular events (MACE – heart attack, stroke, or cardiovascular death) not solely dependent upon degree of weight loss in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D) | * 20% reduction in risk of major adverse cardiovascular events (MACE – heart attack, stroke, or cardiovascular death) not solely dependent upon degree of weight loss in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D) | ||
| * 24% reduction in the risk of kidney failure events and death from kidney- or cardiovascular-related causes in the FLOW trial (3,500 patients with T2D and chronic kidney disease) | * 24% reduction in the risk of kidney failure events and death from kidney- or cardiovascular-related causes in the FLOW trial (3,500 patients with T2D and chronic kidney disease) | ||
| - | * reduced apnoea-hypnoea events by 20–24 events per hour more than controls in patients with OSA in the SURMOUNT-OSA trials | + | * reduced apnoea-hypnoea events by 20–24 events per hour more than controls in patients with [[OSA]] in the SURMOUNT-OSA trials |
| * improved knee OA pain and physical functionality in the STEP 9 trial | * improved knee OA pain and physical functionality in the STEP 9 trial | ||
| * can lead to the resolution of [[steatohepatitis|MASH]] without worsening of liver fibrosis | * can lead to the resolution of [[steatohepatitis|MASH]] without worsening of liver fibrosis | ||
glp-1analogs.txt · Last modified: 2026/05/19 22:02 by wh